M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

 
• By Lucie Ellis-Taitt

Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.

Doors
As one door closes will another one open for Merck as it seeks novel pipeline assets?

More from Clinical Trials

More from R&D